In March of 2015, the FDA approved the first biosimilar for use with American patients. In the next five years, the biosimilars market is expected to expand to $60 billion in sales in the U.S. and $127 billion worldwide.
On February 1st, from 10 am – noon, EST, OMedLive in partnership with ClinicalSeriesLive, will be presenting a complimentary online interactive discussion on this class of drugs and their impact on U.S. medicine, “The Advancement of Biosimilars: A New Frontier in Medicine.”
We invite HCPs to discuss biosimilars with Jonathan Kay, MD, Professor of Medicine, University of Massachusetts Memorial Medical Center, Alissa Segal, PharmD, CDE, CDTC, Clinical Pharmacist, Joslin Diabetes Center, and Andrew Evans, DO, MSc, Professor, Tufts University School of Medicine. They will be discussing patient use and answering your questions in real-time.
We look forward to hearing from you and we will report the results in a subsequent post. In the meantime, join the conversation by registering for our event, “The Advancement of Biosimilars: A New Frontier in Medicine.” The session will cover:
- The difference between biologics and biosimilars and how they are different from generic drugs
- The regulatory pathway for this class of drugs including manufacturing, analytical, pharmacokinetic/pharmacodynamics and preclinical requirements
- Clinical research for approved and emerging options that demonstrate biosimilarity compared to the branded products
- Therapeutic areas that rely on biologics and how biosimilars can broaden treatment options
- The uncertainty surrounding safety and effectiveness of biosimilars
Thanks for contributing to our poll, and we hope to see you on February 1st.
Disclaimer: All PlatformQ Health articles, reports, summaries, and recaps of events are for informational purposes. The quotes and opinions of the speakers covered are not to be taken as direct advice for individual patients. Patients should always seek care from qualified, properly accredited healthcare professionals.